- Home
- JLS vs UNCY Comparison
JLS vs UNCY Comparison
Compare JLS & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JLS | UNCY |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.9M | 141.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | JLS | UNCY |
|---|---|---|
| Price | $18.44 | $6.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 26.6K | ★ 488.8K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 9.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.48 | $3.71 |
| 52 Week High | $17.97 | $11.00 |
Technical Indicators
Market Signals| Indicator | JLS | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 56.58 | 62.26 |
| Support Level | $18.12 | $6.01 |
| Resistance Level | $18.48 | $7.19 |
| Average True Range (ATR) | 0.15 | 0.47 |
| MACD | 0.03 | 0.10 |
| Stochastic Oscillator | 94.48 | 85.89 |
Price Performance
Historical ComparisonAbout JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. Its investment objective to generate high current income through opportunistic investments in securitized credit.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.